WASHINGTON — Sen. Rand Paul, R-Ky., is renewing his criticism of former National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci, saying an upcoming congressional hearing could shed new light on U.S.-funded research involving coronaviruses and long-running questions about gain-of-function research.
In a social media post, Paul argued that Fauci’s defense over the past several years has centered on the claim that research funded through the National Institutes of Health did not meet the government’s technical definition of “gain-of-function.”
Paul rejected that distinction.
“Making a virus more transmissible and more lethal to humans is gain-of-function research, whatever label they slap on the grant paperwork,” Paul wrote. He further alleged that Fauci “knew what he funded” and “lied to Congress.”
Paul also pointed to a congressional hearing scheduled for July 29, saying lawmakers intend to further examine what federal officials knew about research grants connected to coronavirus studies and whether Congress received accurate testimony.
The issue has been a source of political and scientific debate since the COVID-19 pandemic began.
Supporters of Fauci have maintained that NIH-funded research complied with federal policies in place at the time and that the grants in question did not meet the government’s formal definition of prohibited gain-of-function research. Fauci has repeatedly denied lying to Congress and has defended his testimony before lawmakers.
Critics, including Paul, argue that regardless of the terminology used by federal agencies, research designed to increase a virus’s transmissibility or pathogenicity should be considered gain-of-function research. They contend that federal officials have relied on technical definitions to avoid accountability and that Congress deserves a full accounting of how taxpayer dollars were used.
Questions surrounding U.S. funding for coronavirus research, including grants awarded through EcoHealth Alliance to research partners in China, have fueled years of congressional investigations, inspector general reviews and public debate over laboratory safety and federal oversight.
The origin of COVID-19 also remains the subject of ongoing investigation. Federal agencies have reached differing assessments regarding whether the pandemic began through natural animal-to-human transmission or a laboratory-related incident. No definitive conclusion has been reached that is accepted by all U.S. intelligence agencies.
The upcoming hearing is expected to revisit those issues, including grant oversight, research classifications, biosafety standards and previous testimony provided to Congress.
For many Americans, the hearing represents more than another political dispute.
It is about transparency, accountability and restoring public confidence in the institutions responsible for protecting public health. Regardless of where the evidence ultimately leads, lawmakers from both parties are expected to continue examining how risky pathogen research is funded and whether additional safeguards are needed to prevent future pandemics.
Original article
Comments